Understanding the Current Rating
The 'Hold' rating assigned to Mankind Pharma Ltd indicates a balanced outlook where the stock is expected to perform in line with the broader market or sector averages. This rating suggests that investors should maintain their existing positions rather than aggressively buying or selling the stock at this time. The assessment is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals.
Quality Assessment
As of 13 June 2026, Mankind Pharma demonstrates a strong quality profile. The company boasts a high Return on Capital Employed (ROCE) of 20.79%, signalling efficient use of capital to generate profits. This level of management efficiency is a positive indicator for long-term sustainability. Additionally, the company maintains a low Debt to EBITDA ratio of 1.74 times, reflecting a robust ability to service its debt obligations without undue financial strain. Operating profit has grown at an annualised rate of 20.15%, underscoring healthy operational performance and growth momentum.
Valuation Considerations
Despite the strong quality metrics, Mankind Pharma is currently rated as 'expensive' in terms of valuation. The stock trades at an Enterprise Value to Capital Employed ratio of 5, which is higher than the average for its peer group. The company’s ROCE of 13.3% relative to this valuation suggests that investors are paying a premium for the stock’s earnings quality and growth prospects. The Price/Earnings to Growth (PEG) ratio stands at 32.7, indicating that the market has high expectations for future earnings growth. While the valuation is on the higher side, it remains within a fair range compared to historical averages of similar companies in the Pharmaceuticals & Biotechnology sector.
Financial Trend and Recent Performance
The latest data as of 13 June 2026 shows that Mankind Pharma has delivered modest returns over the past year, with a 1-year return of +0.44%. More notably, the company’s profits have increased by 1.6% over the same period, reflecting steady financial health despite market fluctuations. Quarterly results for March 2026 highlight strong operational metrics, including an Operating Profit to Interest ratio of 6.56 times and an Operating Profit to Net Sales ratio of 27.01%. Profit Before Tax excluding other income reached ₹568.04 crores, marking a peak in recent quarters. These figures indicate that the company continues to generate solid earnings and maintain operational efficiency.
Technical Outlook
From a technical perspective, Mankind Pharma exhibits a mildly bullish trend. The stock has shown positive momentum with a 6-month return of +9.67% and a year-to-date gain of +8.84%. Shorter-term movements also reflect stability, with a 1-day gain of 0.79% and a 1-week increase of 2.29%. This technical strength supports the 'Hold' rating by suggesting that while the stock is not in a strong buy zone, it is maintaining upward momentum and investor interest.
Institutional Confidence
Institutional investors hold a significant 24.7% stake in Mankind Pharma, which is a positive sign for retail investors. These investors typically have greater resources and expertise to analyse company fundamentals, and their confidence can provide stability and support for the stock price. High institutional ownership often correlates with better governance and transparency, factors that contribute to the company’s overall quality assessment.
Sector and Market Context
Mankind Pharma operates within the Pharmaceuticals & Biotechnology sector, a space characterised by steady demand and innovation-driven growth. The midcap company’s current market capitalisation places it in a competitive position to capitalise on sector trends while managing risks associated with smaller market players. The stock’s performance relative to sector benchmarks and peer valuations suggests that it remains a viable holding for investors seeking exposure to pharmaceutical growth without excessive risk.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
What the Hold Rating Means for Investors
For investors, the 'Hold' rating on Mankind Pharma Ltd suggests a cautious but steady approach. The company’s strong quality metrics and positive financial trends provide a solid foundation, yet the relatively expensive valuation tempers enthusiasm for aggressive accumulation. Investors currently holding the stock may consider maintaining their positions to benefit from ongoing operational strength and sector tailwinds, while new investors might wait for more attractive valuation levels or clearer technical signals before entering.
Summary of Key Metrics as of 13 June 2026
To recap, the stock’s Mojo Score stands at 65.0, reflecting a balanced outlook. The company’s financial health is underpinned by a high ROCE of 20.79%, a low Debt to EBITDA ratio of 1.74, and consistent operating profit growth of 20.15% annually. The valuation remains on the expensive side, with an Enterprise Value to Capital Employed ratio of 5 and a PEG ratio of 32.7. Technical indicators show mild bullishness, supported by positive returns across multiple time frames. Institutional holdings at 24.7% further reinforce confidence in the company’s prospects.
Investor Takeaway
In conclusion, Mankind Pharma Ltd’s current 'Hold' rating by MarketsMOJO reflects a nuanced view that balances strong operational performance and quality against valuation concerns. Investors should monitor the company’s financial trends and market conditions closely, as shifts in valuation or technical momentum could influence future recommendations. For now, the stock remains a steady choice within the Pharmaceuticals & Biotechnology sector, suitable for those seeking moderate exposure with a focus on quality and stability.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
